ArticleJournal of inflammation research2025
Oligoclonal Bands as Predictors of Disease Severity and Prognosis in Anti-NMDAR Encephalitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Oligoclonal bands (OCBs) are frequently observed in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, though their clinical significance remains unclear. This study explored the association between OCBs and clinical manifestations, disease severity, and prognosis in patients with anti-NMDAR encephalitis, and evaluated its potential clinical significance. Patients and Methods: This retrospective study included 85 anti-NMDAR encephalitis cases treated at the First Affiliated Hospital of Guangxi Medical University between June 2017 and January 2024. Participants were grouped into OCB-positive (n=47) and OCB-negative (n=38) groups to analyze disease severity and prognosis. Disease severity was assessed using the Clinical Assessment Scale for Autoimmune Encephalitis (CASE) and modified Rankin Scale (mRS). Prognostic stratification using discharge mRS scores categorized patients into mild-moderate group (mRS<3) and severe group (mRS≥3), with multivariable regression analysis identifying key prognostic predictors. Results: The OCB-positive group exhibited more severe clinical manifestations, including severe seizure types, disturbance of consciousness, movement disorders, and a higher incidence of intensive care unit (ICU) admission. OCB-positive patients exhibited significantly elevated cerebrospinal fluid (CSF) protein levels and neutrophil percentage in peripheral blood. Additionally, OCB-positive patients showed markedly higher median scores on both the mRS and CASE scales than OCB-negative patients at all time points (admission to last follow-up). Multivariable regression analysis identified two prognostic factors of unfavorable outcomes in anti-NMDAR encephalitis: the presence of OCBs (OR 3.741, 95% CI 1.026-13.637; Conclusion: OCB positivity correlates with heightened disease severity and unfavorable prognosis in anti-NMDAR encephalitis, supporting its utility as a prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.